Calico Appoints Michael Lenardo, M.D., as Chief Scientific Officer
/PRNewswire/ -- Calico Life Sciences LLC (Calico), a biotechnology organization focused on the biology of aging and age-related diseases, and founded by...
Stay updated with breaking news from Michael Lenardo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Calico Life Sciences LLC (Calico), a biotechnology organization focused on the biology of aging and age-related diseases, and founded by...
The FDA has approved Veopoz (pozelimab-bbfg) for the treatment of CD55-deficient protein-losing enteropathy, also known as CHAPLE disease.
TARRYTOWN - Regeneron Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration has approved Veopoz for the treatment of adult and pediatric patients 1 year of age and older with...
18.08.2023 - CHAPLE is an ultra-rare hereditary disease that can cause potentially life-threatening gastrointestinal and cardiovascular symptoms Approval represents 10th FDA-approved medicine invented by Regeneron With the approval of Veopoz, the ...
CHAPLE is an ultra-rare hereditary disease that can cause potentially life-threatening gastrointestinal and cardiovascular symptoms Approval represents 10th FDA-approved medicine invented by...